Colle Capital

Colle Capital is a New York-based early-stage venture firm with a generalist software, consumer, and healthcare mandate, founded by Victoria Grace. The firm’s public posture is thesis-light but operationally engaged, with a portfolio that spans technology, healthcare, and consumer brands. Healthcare exposure is real, with deals across digital health, clinical AI, and healthcare services where the business is software-shaped or services-led. Stage focus is seed and Series A, with check sizes plausibly $500K to $3M and a willingness to participate in primary-led rounds. For healthcare AI founders, Colle is most relevant as a generalist seed and Series A co-investor: they bring NYC operator relationships, brand-name visibility, and pragmatic governance, but they are not a healthcare-specialist lead and will defer to domain co-investors on clinical and regulatory diligence. Founders who should approach: NYC-area or East Coast healthcare AI teams with traction, founders looking for a network-rich co-investor that can fill out a round, and software-shaped businesses with manageable regulatory profiles — RCM, scheduling, ambient documentation, telemedicine, mental health, women’s health, employer health. Founders who should not approach: regulated medical devices, biotech, and clinical AI requiring deep specialist domain leads with FDA pathway expertise. Colle’s value-add is operator network, brand, and downstream investor introductions. Entry path is warm introduction through portfolio founders, the NYC seed-stage operator and angel network, or co-investors active in NYC digital health. Their LinkedIn and Crunchbase pages list partners and portfolio. Direct LinkedIn outreach is feasible when paired with a clear thesis-fit articulation and strong metrics. Treat Colle as round-completion capital alongside a domain-specialist lead.